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SERD selective estrogen receptor down-regulator 
SERM selective estrogen receptor modulator 
SHR steroid hormone receptor 
SLNB sentinel lymph node biopsy 
TAM tamoxifen 
TGZ troglitazone 
THR thyroid hormone receptor 
TNBC triple-negative breast cancer 
TRE thyroid hormone response element 
TZD thiazolidinedione 
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4. Introduction 
4.1  Breast cancer 
4.1.1 Epidemiology 
Breast cancer (BC) is the most common female malignancy and the main cause of cancer-related 
death worldwide [1]. In 2018, 2.1 million newly diagnosed cases and 0.6 million related deaths have 
been recorded, respectively accounting for 24.2% of total new cancer cases and 15.0% of all deaths 
in women [2]. It is noteworthy that although the mortality rates are decreasing in developed 
countries due to the advances in cancer screening and adjuvant therapy, the incidence rates of BC 
are increasing in most countries whereas death rates are much higher in less developed regions [3, 
4]. Therefore, addressing the global BC issue is a huge challenge and it is necessary to develop early 
detections and novel treatments for BC. 
4.1.2 Local management: surgery and radiotherapy 
The complexity and heterogeneity of BC require a comprehensive and multidisciplinary approach 
adapted to each patient. The primary local and regional BC treatment remains surgical intervention, 
with a constant evolution from the Halsted radical mastectomy [5] from the 19th century to the Fisher 
modified radical mastectomy currently [6, 7]. Breast-conserving surgery followed by radiotherapy 
is established for most early BC cases because of developments in surgical techniques and 
neoadjuvant systematic therapies [8]. Some researchers demonstrated that the overall survival (OS), 
disease-free survival (DFS) and relapse-free survival (RFS) are equivalent to those of mastectomy 
[7, 9]. Reconstruction is a selection for women electing mastectomy with a relatively small breast 
in setting of huge tumor, extensive calcifications, or multicentric disease [10].  
In addition to tumor size, axillary lymph node status acted as a prognostic factor in early BC 
and provides guidance for personalized treatment. Sentinel lymph node biopsy (SLNB) replaced the 
traditional axillary lymph node dissection (ALND) in node-negative BC patients, preventing them 
from lymphedema, shoulder dysfunction and other complications [8, 10, 11]. ACOSOG Z0011 trial 
proved that no survival difference was found between ALND and SLNB [12]. After 10 year follow-
Introduction 
8 
up, early-stage BC patients with 1 or 2 SLN metastases treated by SLNB alone had noninferior 
outcome in OS compared with those treated with ALND [13]. 
Radiotherapy was recommended as a critical adjuvant treatment for women after breast-
conserving surgery or mastectomy with high-risk clinical or pathologic factors (e.g. positive lymph 
nodes, large tumor size or lymphovascular invasion), beneficial for reducing local recurrence [14, 
15]. In addition, the main complications of radiotherapy comprise cutaneous, pulmonary and cardiac 
toxicity and radiation techniques development (e.g. intensity modulated radiation therapy) and 
facilities implementation (e.g. deep inspiration breath hold technique) would contribute to lower 
rates of adverse events [16]. 
4.1.3 ER, PR and endocrine therapy 
Excessive exposure to estrogen, acting through estrogen receptors, plays an important role in the 
development of BC by stimulating cell proliferation and initiating mutations during DNA 
replication [17]. The majority of BC (approximately 70%) express ERα (mostly named ER), 
progesterone receptor (PR) or both [18, 19] and assessment of ER and PR (together termed as 
hormone receptor – HR) status has become the standard of care for BC patients. Patients with HR 
positive BC exhibit lower recurrence and better outcome compared with the HR negative group and 
HR was identified as an independent predictor in BC [20, 21]. Besides, the expression of PR is 
primarily regulated by ERα at the transcriptional level [22]. Loss of PR expression is correlated to 
a worse outcome in luminal cancers [23]. 
ER and PR belong to the steroid hormone receptor (SHR), a subfamily of nuclear receptor 
superfamily [22, 24, 25]. Guideline recommendations of immunohistochemical testing suggested 1% 
or more nuclear ER or PR staining as positive [1] and endocrine sensitivity was determined by the 
intensity of ER and PR positivity [8]. Gene expression profiling identified a molecular subtype in 
BC, “luminal-like”, divided to A and B. Luminal B cancers were characterized as higher expression 
of proliferation genes (Ki-67) compared with luminal A [23, 26].  
Endocrine therapy represents an important strategy in the management of early and advanced 
hormone positive BC [27], including commonly ovarian suppression, selective estrogen receptor 
modulators (SERMs) and down-regulators (SERDs) and aromatase inhibitors (AIs), which was 
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given consecutively after surgery or chemotherapy [8, 28]. For premenopausal ER-positive BC 
patients with sufficient risk factors for recurrence, ovarian suppression was recommended to 
combine with adjuvant endocrine therapy [29]. Tamoxifen (TAM), a SERM, acts as a competitive 
inhibition of estrogen binding to ER and consequently suppresses estrogen-dependent gene 
transcription, cell proliferation and tumor growth [30]. Whereas, fulvestrant, a SERD, binds to ER 
and makes it accelerated degradation, leading to reduction of cellular ERα levels[31]. AIs (e.g. 
anastrozole, exemestane and letrozole), usually applied in postmenopausal women by reducing the 
production of estrogen by blocking the aromatase enzyme activity (also known as CYP19A1 [32]), 
decrease the recurrence rates and mortality rates compared with TAM [33, 34]. ATLAS trial 
demonstrated prolongation of TAM treatment for ER-positive BC from 5 years to 10 years produces 
a further reduction in recurrence and mortality [35].  
4.1.4 HER and anti-HER therapy 
13-15% of BCs overexpress the HER2 tyrosine kinase receptor, divided to two subgroups: luminal 
B-like and non-luminal, which have a highest death rate compared with other subgroups [1]. Human 
EGFR (also called ErbB or HER) family comprises four transmembrane receptor tyrosine kinases: 
HER1 or EGFR, HER2, HER3 and HER4. When active, formation of homo- and heterodimers could 
activate downstream pathways: PI3K/AKT, Ras/Raf/MEK/ERK and PLCγ pathway [36]. Among 
them, HER2, overexpressed in 25%-30% of BC, correlates with poor prognosis and an important 
therapeutic target [37]. Trastuzumab, a humanized monoclonal antibody targeting HER2, became a 
successfully clinical biological drug, together or sequential with chemotherapy, as adjuvant or 
neoadjuvant treatment, which significantly increased OS and DFS in women with HER2-positive 
breast cancer [38]. Although no ligand is known for HER2, it appears to cooperate with other ErbB 
receptors (HER3/HER4) in neoplastic progression. Moreover, HER3 serves as an indispensable 
partner of HER2 dimerization and an essential function of proliferation on HER2-positive BC. Thus, 
drugs targeting HER3 may enhance the efficacy of dual HER2-targeted approaches [39]. The 
function of HER4 in BC is controversial, resulting in good or bad outcomes. It works not only in 
cell cycle arrest, differentiation, apoptosis but also in cell proliferation [40]. Besides, upregulation 
of nuclear HER4 led to worse trastuzumab response and poorer survival in HER2-positive BC, 
whereas cytoplasmic HER4 seems related to longer OS [40, 41]. Overexpression of EGFR is 
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frequently observed in triple-negative BC (TNBC) and inflammatory BC (an aggressive subtype), 
causing worse prognosis [42, 43]. However, EGFR-targeted therapies, monoclonal antibodies and 
tyrosine kinase inhibitors, had no significant results in clinical trials of BC [44]. Nevertheless, anti-
HER therapy or combined with other targeted drugs may be a promising strategy against BC. 
4.1.5 TNBC and other potential targets 
TNBC represents approximately 15%-20% of all BC, characterized as lack of ER, PR and HER2 
expression. This term is more aggressive with higher relapse rates and poorer overall outcome than 
other types of BC, distinctly related to large size, high grade and lymph node involvement [1, 45, 
46]. Six subtypes were identified by gene expression profile analysis, including basal like 1 and 2, 
immunomodulatory, mesenchymal, mesenchymal stem–like, and luminal androgen receptor [1, 47, 
48]. TNBC patients usually have a better pathologic complete response rates (pCR) after 
neoadjuvant chemotherapy and those who achieve pCR have a long-term survival [49]. Current 
treatments for TNBC are limited to cytotoxic chemotherapy, due to the lack of effective targets. 
BRCA1/2 mutations are more likely to cause hereditary breast and ovarian cancers and account 
for around 20% of patients with TNBC, which pattern is susceptible to DNA-damaging agents, 
platinum compound and poly (ADP ribose) polymerase inhibitors [50]. p53 is another mutant gene 
considerably associated with TNBC and agents (e.g. PRIMA-1 and APR-246) restoring its wild-
type properties maybe new treatments for BC [51]. Dysfunction of PI3K-AKT-mTOR signaling 
pathway, such as PIK3Ca mutation and loss of PTEN, gives rise to progress in breast tumorigenesis 
[52]. In addition, PIK3Ca mutation is frequently observed in luminal androgen receptor subtype cell 
lines and make it sensitive to PI3K/mTOR inhibition [53]. Thus, combination of anti-androgen and 
other target therapies may optimize current strategies in TNBC. More and more attentions are 
diverted to individual and personalized therapy from standardized system based on TNM stages. 
Precision treatment of BC is defined by analysis of immunohistochemical markers and gene 
expression, guiding treatment plans and response assessments.
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4.1.6 Chemotherapy and resistances 
Apart from endocrine therapy, anti-HER2 and more recent targeted therapy, chemotherapy was 
regarded as a conventional and effective adjuvant systemic regime, which indications depend on 
tumor grade, lymph node involvement or cell proliferation status (widely estimated by Ki-67 index 
[54]). Moreover, multiparameter gene expression assays were presented for risk assessment and 
prediction of chemotherapy benefit in patients with luminal-like disease, such as Oncotype DX and 
MammaPrint [8, 55]. The routine agents of current cytotoxic therapy are anthracylines and/or 
taxanes given in combination or in sequence, for both early and advanced stage BC [55]. Of note, 
dose-dense chemotherapy leads to a better prognosis [56]. Besides, the purpose of chemotherapy in 
metastatic BC is to maintain quality of life, relieve symptoms and prolong life [8].  
Drug resistance of BC limiting the chemotherapy efficacy, brings a great challenge to survival 
of patients, which mechanisms underlying chemoresistance were defined. Higher expressions of 
twist gene and multidrug resistance 1 gene suggested as a prediction for response to chemotherapy 
in BC [57, 58]. ATP-binding cassette transporters remove chemotherapeutic drugs from cells and 
result in chemoresistance [59]. Regulation of the behavior of tumor cells by cytokines and survival 
of cancer stem cells promoted chemoresistance [60]. In addition, other mechanisms include DNA 
damage repair [61], tumor microenvironment [62] and microRNAs [63].  
Mutations of ER gene and lack of ER and PR expression are identified as causes of endocrine 
resistance in BC [64]. Cyclin-dependent kinases (CDKs) play crucial roles in regulation of cell cycle 
by synergizing with cyclin. CDK4/6 inhibitors contribute to overcome endocrine resistance BCs 
combined with anti-estrogen or anti-HER2 therapy [65]. The PI3K/AKT pathway and ER signaling 
crosstalk is correlated with effectiveness of anti-estrogen drugs [66, 67]. Otherwise, epidermal 
growth factor receptor (EGFR, ErbB) family, STAT family and NF-κB family are potential targets 
for combination with endocrine therapeutic strategies in ER-positive BC [68-70]. Furthermore, 
inhibitors of CDK4/6, PI3K and mTOR have been applied in clinical trials with benefits for 
advanced HR-positive, HER2-negative BC. Ribociclib (CDK4/6 inhibitor) plus endocrine therapy 
improved progression-free survival (PFS) and palbociclib, combined with fulvestrant, could 
increase OS but the difference was not significant [71-73]. PI3K inhibitors, buparlisib and alpelisib, 
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combined with fulvestrant, resulted in a longer PFS in endocrine-resistant and PI3CA-mutated 
patients, respectively [74, 75]. Everolimus (mTOR inhibitor) plus an AI, improved PFS in patients 
with nonsteroidal AIs [76]. 
Therefore, understanding resistance mechanisms and exploring novel approaches are beneficial 
to overcoming chemoresistance, and resistance to all targeted therapies. 
4.2 Nuclear receptor 
4.2.1 An overview 
The human nuclear receptor (NR) superfamily contains 48 members, some of which are DNA-
binding transcription factors activated by endogenous and exogenous ligands and some of which 
are so-called “orphan receptors”, because the ligands have not been identified [77]. NRs play a 
crucial role in a range of physiological process, such as metabolism, homeostasis and immune 
response. Dysfunction of NR signaling pathway lead to numerous diseases including obesity, 
diabetes and cancer [78, 79]. All NR proteins have a common modular, highly conserved structure 
with four major domains (Figure 1) [25]. The C-terminal ligand-binding domain (LBD), containing 
ligand-induced activation function (termed AF-2), involves in transcriptional activity by regulation 
of ligand binding and coregulator recruitment. The most conserved DNA-binding domain (DBD) 
located in the central C region of NR protein with two zinc finger motifs. LBD and DBD could 
mediate the dimerization of NRs in some cases. LBD and DBD are linked by a short hinge region 
responsible for nuclear localization signal (NLS). In contrast to AF-2, AF-1 is positioned in the 
poorly identified N-terminal A/B region, interacting with coregulators through a ligand-independent 
way [80, 81]. Thus, NRs could activate or repress target gene transcription functions by ligand 
dependent and independent regulations. 
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Figure 1: The structure of nuclear receptor. 
 
 NRs have been classified as into four subtypes due to the classical genomic mechanisms [79, 
82]. Type I NRs include Steroid Hormone Receptors (SHRs), such as ER, PR, androgen receptor, 
glucocorticoid receptor and mineralocorticoid receptor. They disassociate from heat shock proteins 
(HSPs) and form homodimers after ligand activation in the cytoplasm. Then dimers translocate to 
the nucleus and bind to specific sequences of DNA known as hormone response elements (HREs), 
which subsequently regulate the transcription of target genes by recruiting coactivators [83, 84]. 
Type II NRs, such as thyroid hormone receptors (THR) and peroxisome proliferator activated 
receptors (PPAR), are retained in the nucleus binding as heterodimers with retinoid X receptors 
(RXR) to specific DNA response elements regardless of ligand activation by changes in dissociation 
of corepressors and recruitment of coactivators [85]. Type III NRs, such as vitamin D receptor, 
function similarly to type I NRs but bind to direct repeat instead of inverted repeat HREs. Type IV 
NRs instead bind as a monomer to half-site HREs. Alternate mechanism of NR cross-talk has been 
recognized as “nongenomic” actions independently of transcriptional regulation [86, 87]. The 
genomic process generally requires a prolonged series of actions (at least 30 to 60 minutes to 
modulate the transcription processes), whereas nongenomic type elicits rapid cellular effects within 
seconds or minutes and is not repressed by inhibitors of transcription or translation [88-91]. The 
rapid nongenomic actions of NRs initiate by binding to membrane receptors or interacting with 
molecules, such as G proteins, ion channels, protein kinases, Src tyrosine kinase, PI3K and MAPK. 
One example is the presence of SHRs or THRs at the mitochondrial or plasma membranes, leading 
to the rapid nongenomic signaling processes [92-94]. Thus, subcellular localization of NRs may 
play different roles in genomic and nongenomic actions, which should be considered in the 
development of NR-related diseases. 
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In BC, ER and PR, two members of NR superfamily, are of particular importance in 
tumorigenesis and prognosis, which give rise to more precise routine diagnosis for molecular 
subtype in all patients. Drugs targeting ER, such as TAM [30], fulvestrant [95], and more recently 
developed AIs [33] achieve a great success in current BC treatment strategies. However, it is still a 
tremendous challenge to make relevant therapies for advanced or metastatic cases and TNBC 
disease. More study of NR-related signaling pathway may provide novel therapeutic targets for BC. 
4.2.2 PPARγ 
PPARs are ligand-dependent transcription factors, which consist of three major subtypes, 
commonly designated as PPARα, PPARβ/δ and PPARγ encoded by separate genes [96, 97]. PPARs 
play critical roles in lipid homeostasis, glucose metabolism, inflammatory response and cancer 
development [98, 99]. The human PPARγ gene is located in chromosome 3p25 [100]. PPARγ is the 
most extensively described isoform of PPARs, which influences inflammation, cell proliferation, 
differentiation, apoptosis and tumor angiogenesis [101]. Positive immunoreactivity of PPARγ was 
strong in the nucleus of normal and benign breast tissues, however, a decreased or no staining was 
shown in malignant tissues [102-104]. High levels of PPARγ predominantly in either nucleus or 
cytoplasm were correlated with a longer survival and favorable clinical characteristics, such as 
smaller size, lower grade, earlier stage and ER positivity [102-106]. Besides, in a study previously 
published in our laboratory, cytoplasmic PPARγ showed stronger expression in BRCA1-mutant BC 
than sporadic cases with no relation to prognosis [107]. In a clinical study with a PPARγ ligand, 
HER2-positive BC patients with diabetics had a long-term survival after metformin and 
thiazolidinedione (TZD) therapy [108], indicating activation of PPARγ may play a positive role in 
repression of BC. However, patients with metastatic BC had no benefits from treatments with 
troglitazone (TGZ) [109] or rosiglitazone (BRL) [110].  
 The function of PPARγ in tumorigenesis seems contradictory. The oncogenic role of PPARγ 
has been reported in several studies, including BC [111-114]. Enhanced PPARγ signaling induced 
tumor incidence and mortality in transgenic mice with a ligand-independent PPARγ mutant [113]. 
Besides, T0070907, a selective PPARγ antagonist, and the dominant-negative PPARγ mutant, Δ462, 
significantly reduces cellular proliferation, migration and invasion in breast cancer cell lines [114].
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On the other hand, PPARγ acts primarily as a tumor suppressor in most cancers, especially BCs. 
BRL suppressed proliferation in MCF-7 cells line with a PPARγ-dependent manner by 
downregulating PI3K/AKT pathway, which was reversed by ERα antagonist, indicating that ERα 
negatively mediated PPARγ signaling through binding to PPRE. PPARγ activation also induces 
overexpression of PTEN tumor suppressor gene [115]. ERα and PPARγ could compete for BRL, 
mediating each other’s transactivation [116]. In mouse tumor model, PPARγ activation inhibited 
BC progression by upregulating protein tyrosine phosphatase receptor F, a downstream target of 
PPARγ [117]. Moreover, BRL promoted apoptosis by activating Fas/FasL pathways in human BC 
cell lines [118] and induce cell differentiation [119]. The biotinylated form of 15d‑PGJ2 
(b‑15d‑PGJ2) had obvious anti-proliferative and pro-apoptotic effects on MCF-7 and MDA-MB-
231 cell lines compared with 15d‑PGJ2, which was attenuated by PPARγ silencing with a decrease 
of apoptotic markers, PARP‑1 and caspase‑7 [120]. HER2 overexpression in BC cells was 
accompanied with a high level of PPARγ protein, inhibiting PPARγ transcription activation and 
PPARγ ligand-induced cell growth [121]. In addition, PPARγ downregulated CXCR4 expression, 
which played a pivotal role in mediating the development of BC invasion and metastasis. The 
mechanism seemed to be reversed by GW9662, a PPARγ antagonist, and decreased levels of 
phosphorylated FAK, AKT and ERK1/2 in CXCR4 downstream signaling [122]. TGZ inhibited 
TPA induced NF-κB and AP-1 activation and MMP-9 expression, the critical enzyme for invasion 
and metastasis, through a PPARγ-dependent mechanism [123]. 
 Besides the genomic effects of the NR, many other nongenomic effects have been described, 
not only for ER [124], with membrane or cytoplasmic expression. Nuclear export of PPARγ is 
initiated via MAPK/ERK/MEK1/2 signaling, which restrains PPARγ transactivate nuclear target 
genes and thereby inhibits its genomic function [125, 126]. uPA mediated PON 1 expression in 
hepatocytes by regulating subcellular compartmentalization of PPARγ and induced PPARγ nuclear 
export in a MEK-dependent manner [127]. Fatty acids, acting as PPARγ agonists, had antineoplastic 
effects in BC cells with inhibition of ERK1/2 phosphorylation and nuclear translocation of PPARγ 
[128-130]. In another study, nuclear immunoactivity of PPARγ was observed in MCF-7 cell line or 
ER-positive tissues, whereas MDA-MB-231 cells, or ER-negative tissues, showed a cytoplasmic 
localization strongly related with S-phase kinase protein (Skp2) expression, which is related to 
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malignancy in certain tumors. Down-regulated Skp2 could reverse tetradecanoyl phorbol acetate-
induced nuclear export of PPARγ in MEK1-dependent pathway [131]. These findings suggest that 
nuclear translocation of PPARγ may play an important role in antitumor effects and suggest that the 
study of the intracellular distribution of PPARγ may give new insights to identify novel therapy for 
BC. 
4.2.3 THR 
As many other NR, TH modulate numerous physiological activities, including development, 
differentiation, growth and metabolism, again by two distinct pathways, genomic and nongenomic. 
The classical genomic mechanisms are mediated mostly by T3-THR complex binding to TH 
response elements (TREs). Two isoforms, THRα and THRβ, are encoded by THRA and THRB genes 
which located on chromosome 17 and 3 [132-134]. The nongenomic actions of TH are related to 
plasma membrane, mitochondria or cytoplasm locations with receptors homologous or 
nonhomologous to THRs, such as integrin αvβ3 [132, 135]. The TH status and thyroid disorders 
have a strong correlation with the development of BC. High levels of T3 was observed in BC 
patients compared to benign breast tumor, positively related to aggressive BC characters, such as 
larger tumor, lymph node metastases and negative ER and PR expression [136, 137]. In addition, 
BC patients were inclined to thyroid enlargement and a meta-analysis study showed that BC or 
thyroid cancer predisposed an individual to developing the other [138, 139]. These findings 
indicated a significant association between TH signaling and BC. 
 Several previous studies reported that either THRα or THRβ expression decreased in BC 
compared with normal breast tissues, indicating downregulation of THR during breast 
carcinogenesis [140-143]. Loss of nuclear THRα expression was correlated with larger and higher 
grade tumor [143] and nuclear THRα2 was an independent prognostic factor in improved OS [144, 
145]. Other studies figured THRβ functioned as a tumor suppressor in BCs. Low THRβ levels 
predicted poor outcomes and enhanced resistance to chemotherapy by cAMP-PKA signaling 
pathway [146]. In BRCA1-mutated BC, THRβ were overexpressed compared with sporadic cases 
but had a positive prognostic result whereas THRα reduced survival [147]. THRβ inhibited tumor  
growth by activating apoptosis and decreasing proliferation via JAK-STAT-cyclin D pathways in
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the xenograft mouse model [148]. The suppression of oncogenic RUNX2 activity was dependent 
on THRβ, not THRα, in triple negative MDA-MB-231 cell line [149]. Moreover, mutation of THRβ 
promoted the development of BC via aberrant activation of STAT5 [150], which was consistent 
with the result of another study regarding THRβ1 gene mutation in tumorigenesis of Chinese BC 
population [151]. In addition to other preclinical researches, THRβ1 could inhibit cell proliferation, 
invasiveness and metastasis formation in BC cell lines [152, 153].  
Studies of the protein expression and subcellular localization about THRβ were limited. 
Shuttling of THR between the nucleus and cytoplasm was induced by TH, indicating that THR 
mislocalization may contribute to the development of some types of cancer [133, 154, 155]. One 
study reported that THRβ1 expression was predominantly in cytoplasm in BC, and positively 
associated with ER-positive tumors, small tumors, lymph node negative status and longer survival 
[156]. In another previous study, THRβ was described as expressed in nuclei of benign and 
carcinoma in situ tissues, and in the cytoplasm of normal breast and infiltrative BC cells [157]. 
Besides, overlapping genomic and nongenomic actions of TH are observed between integrins and 
THR [93]. TH binding to αvβ3 induced nuclear translocation of THRβ1 through MAPK/MEK/ERK 
pathway [158]. In addition, this complex also regulates expression of the THRβ1, ERα, and 
cyclooxygenase-2 (COX-2) genes and modulates post-translational modifications of THRβ1 [159, 
160]. Therefore, exploring nongenomic action of THRs and its subcellular localization is essential 
in BC development. The cross-talk between genomic and nongenomic actions of THR may provide 
new targets for BC treatment. 
4.3 Cyclooxygenase 
Targeting prostaglandins (PGs) pathway potentially plays a positive role in prevention and treatment 
of cancers. Biosynthesis of PGs, some belonging to PPARγ ligands, from arachidonic acid (AA) is 
catalyzed by a key enzyme, Cox, which has two isoforms, Cox-1 and Cox-2 [161, 162]. Cox-1 is 
constitutively expressed in many normal cells, whereas Cox-2 is generally considered induced by 
inflammatory cytokines and growth factors, resulting in carcinogenesis of many tissues [163, 164]. 
A meta-analysis study revealed that increased expression of Cox-2 in BC ranged from 27.9% to 
81.4%, significantly correlated with poor OS and adverse features, such as large tumor size and 
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lymph node invasion [165]. Prostaglandin E2 (PGE2), production via Cox-2, induced CYP19 
expression and aromatase activity, leading to the development of ER-positive BCs [166, 167]. In 
addition, Cox-2 inhibitors decreased incidence and progression of BC through improving apoptosis 
and repressing proliferation and angiogenesis [168]. Combination of specific Cox-2 inhibitor and 
PPARγ agonist resulted in growth inhibition in a mouse model of mammary adenocarcinoma [169]. 
Compared with Cox-2, less attention was taken to Cox-1 in tumors, although both selective and 
nonselective Cox inhibitors prevent mammary tumors [170]. Fewer studies demonstrated the tumor 
suppression of selective Cox-1 inhibitors in BC, such as SC-560, catechin and FR122047. More 
interestingly, combination of Cox-1 and Cox-2 inhibitors had an addictive effect on tumor 
repression in BC cell lines [171-173]. Besides, Corticotropin-releasing factor, a hypothalamic 
neuropeptide, promoted cell motility and invasiveness through production of PGs via Cox-1 not 
Cox-2 in BC cell line [174]. Another study elucidated that the antitumor property of nonsteroidal 
anti-inflammatory drugs by cell differentiation was not dependent on Cox-2 pathway, indicating 
that potential role of Cox-1 in the activation of PPARγ [175]. In summary, the literature strongly 
suggests that both Cox-1 and Cox-2 participate in PGs and PPARγ signaling pathways involved in 
breast tumorigenesis. 
4.4 Aims of the studies 
4.4.1 Subcellular expression of PPARγ and correlation with Cox-1 in 
primary BC tumors 
The role of PPARγ, the most extensively described isoform of PPARs, was controversially 
described as a tumor promoter or suppressor in different cancers. PGs, as PPARγ ligands, are 
produced from the conversion of AA by Cox-1 and Cox-2. The aim of this study was to analyze the 
relevance of combined expression of PPARγ and Cox (especially Cox-1) in BC and correlation of 
the data with several clinicobiological parameters including patient survival. In the Publication I of 
this thesis, we analyzed by immunohistochemistry the subcellular expression of PPARγ and of the 
two Cox proteins in a well characterized 308 primary BC specimens in relation to survival, to 
determine if either one could, independently or in relation to the others, be linked to BC progression.
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4.4.2 Expression and subcellular localization of THRβ1 in primary BC 
tumors 
THRβ1, also belonging to NR superfamily, appears to act as a tumor suppressor in many malignant 
neoplasms. While THRβ1 clearly appears to be a key player in BC carcinogenesis, the importance 
of its subcellular localization remains to be elucidated. The purpose of this study was designed to 
explore the different roles of nuclear-cytoplasmic compartmentalization of THRβ1 in BC tissues. 
Therefore, we investigated the nuclear and cytoplasmic expression of THRβ1 by 
immunohistochemistry in the same cohort with 274 primary BC tumors and analyzed the correlation 
of the results with clinicopathological parameters and clinical outcome. All data were published in 
Publication II of this thesis. 
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7. Summary 
Dysfunction of NR signaling pathway lead to numerous diseases including cancers. NRs regulate 
cellular processes by classical genomic or nongenomic mechanism. In BC, ER and PR, two 
members of NR superfamily, are of particular importance in tumorigenesis and prognosis and drugs 
targeting these two receptors achieve great success. However, it is still a tremendous challenge to 
make relevant therapies for advanced or metastatic cases and TNBC disease. More study of NR-
related signaling pathway may provide novel therapeutic targets for BC. Therefore, we investigated 
subcellular expression of another two NRs, PPARγ and THRβ1, in the same cohort of BC tissues 
and analyzed correlation with several clinicopathological characteristics and patient survival. 
Publication I: Cytoplasmic PPARγ is a marker of poor prognosis in patients with 
Cox-1 negative primary breast cancers 
The aim of this study was to investigate the subcellular expression of PPARγ and related Cox-1 and 
Cox-2 in a cohort of 308 BC tissues and correlate them to survival. Immunohistochemistry was 
performed for PPARγ, Cox-1 and Cox-2 nuclear and cytoplasmic expression, clearly exhibiting that 
PPARγ was expressed in most BC samples with predominantly cytoplasmic location, Cox-1 and 
Cox-2 being only cytoplasmic. Cytoplasmic PPARγ had a positive correlation with Cox-1, Cox-2, 
and other high-risk markers of BC (HER2, CD133, and N-cadherin), whereas inversely with nuclear 
PPARγ and ER expression. Kaplan Meier analysis demonstrated that cytoplasmic PPARγ was a 
significant unfavorable predictor of overall survival in the whole cohort, as well as in the subgroup 
of patients with no Cox-1 expression where it appeared as an independent marker of poor prognosis. 
In addition, to examine the relationship between PPARγ and Cox-1, we identified that Cox-1 was 
associated with good prognosis only in patients with high cytoplasmic PPARγ expression. In 
conclusion, our results suggest that the relative expression of cytoplasmic PPARγ and Cox-1 may 
be essential in BC physiopathology and that both could be defined as potential targets for BC 
personalized therapeutic strategies. 
Publication II: Cytoplasmic and nuclear forms of thyroid hormone receptor β1 
are inversely associated with survival in primary breast cancer 
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This study aimed then to assess the subcellular distribution and prognostic roles of THRβ1 in the 
same cohort (with 274 primary BC). Nuclear THRβ1 was detected in 60.46% of all samples by 
immunohistochemistry, with frequent cytoplasmic location too. In addition, nuclear and 
cytoplasmic THRβ1 were positively associated with each other and both had a strong correlation 
with high-risk markers of BC, as performed in Publication I. Overall survival performed by Kaplan 
Meier analysis demonstrated that high level of cytoplasmic THRβ1 was strongly correlated with 
long-term survival, whereas nuclear THRβ1 had an inverse statistically significant correlation with 
long-term survival. Cox regression model showed that nuclear THRβ1 served as an independent 
marker for unfavorable prognosis, whereas cytoplasmic THRβ1 served as an independent marker 
for favorable one. In conclusion, these data indicate that the subcellular expression of THRβ1 may 
determine specific effects on BC physiopathology. Finally, nuclear THRβ1 expression is another 
negative predictive biomarker which may play a role for BC personalized therapeutic strategies. 
 In conclusion, cytoplasmic PPARγ and nuclear THRβ1 are both regarded as negative survival 
markers to identify high-risk BC subgroups. The cross-talk between genomic and nongenomic 
actions of NRs may play different roles in BC development. Thus, the further study of the 
intracellular distribution of NRs may give new insights to identify novel therapy for BC.  
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8. Zusammenfassung 
Eine Funktionsstörung des Kernrezeptor- (NR) Signalwegs führt zu zahlreichen Krankheiten, 
einschließlich Brustkrebs (BC). NRs regulieren zelluläre Prozesse durch klassische genomische 
oder nichtgenomische Mechanismen. In BC sind Estrogenrezeptoren (ER) und 
Progesteronrezeptoren (PR), zwei Mitglieder der NR-Superfamilie, von besonderer Bedeutung für 
die Tumorentstehung und –prognose. Deshalb sind Arzneimittel, die auf diese beiden Rezeptoren 
abzielen, bei Hormonrezeptor-positiven Patienten erfolgreiche Behandlungsoptionen. Es ist jedoch 
immer noch eine enorme Herausforderung, relevante Therapien für fortgeschrittene oder 
metastatische Fälle und Hormonrezeptor negative und HER2-negative (TNBC)-Erkrankungen zu 
entwickeln. Weitere Untersuchungen des NR-bezogenen Signalwegs könnten neue therapeutische 
Ziele für diese Patientinnen liefern. Daher untersuchten wir die subzelluläre Expression von zwei 
weiteren NRs, PPARγ und THRβ1, in derselben Kohorte von BC-Geweben und analysierten die 
Korrelation mit mehreren klinisch-pathologischen Merkmalen und dem Überleben des Patienten. 
Veröffentlichung I: Zytoplasmatisches PPARγ ist ein Marker für eine schlechte 
Prognose bei Patienten mit Cox-1-negativem primären Brustkrebs 
In einer gut charakterisierten Kohorte von 308 primären BC-Gewebeschnitten wurden die 
zytoplasmatische und nukleare Expression von PPARγ, Cox-1 und Cox-2 mittels 
Immunhistochemie untersucht. Korrelationen mit klinisch-pathologischen- und weiteren 
Merkmalen sowie das Überleben der Patientinnen wurden mit Hilfe statistischer Methoden und 
letzteres unter Verwendung der Kaplan-Meier-Analyse erhoben. PPARγ wurde in fast 58% der 
Proben mit einer vorherrschenden zytoplasmatischen Lokalisation exprimiert. Cox-1 und Cox-2 
waren ausschließlich zytoplasmatisch. Zytoplasmatisches PPARγ war invers mit der nuklearen 
PPARγ- und ER-Expression korreliert, jedoch positiv mit Cox-1, Cox-2 und anderen 
Hochrisikomarkern von BC, z.B. HER2, CD133 und N-Cadherin. Die Gesamtüberlebensanalyse 
zeigte, dass zytoplasmatisches PPARγ in der gesamten Kohorte eine starke Korrelation mit einer 
schlechten Überlebensrate aufwies und in der Untergruppe der Patienten ohne Cox-1-Expression, 
bei denen die zytoplasmatische PPARγ-Expression als unabhängiger Marker für eine schlechte 
Prognose auftrat, noch stärker war. Zur Unterstützung dieses Zusammenhanges zwischen PPARγ 
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und Cox-1 stellten wir fest, dass Cox-1 nur dann zu einem Marker für eine gute Prognose wurde, 
wenn zytoplasmatisches PPARγ mit einem hohen Score exprimiert wurde. Insgesamt lassen diese 
Daten darauf schließen, dass die relative Expression von zytoplasmatischem PPARγ und Cox-1 eine 
wichtige Rolle bei der Onkogenese spielt und als potenzieller Prognosemarker zur Identifizierung 
spezifischer hochriskanter BC-Untergruppen definiert werden könnte. 
Veröffentlichung II: Zytoplasmatische und nukleäre Formen des 
Schilddrüsenhormonrezeptors β1 sind invers mit dem Überleben bei primärem 
Brustkrebs assoziiert 
In einer gut charakterisierten Kohorte von 274 primären BC-Gewebeschnitten wurde THRβ1 
hauptsächlich im Zellkern der Tumorzellen exprimiert, obwohl auch häufig eine zytoplasmatische 
Färbung beobachtet wurde. Sowohl das nukleäre als auch das zytoplasmatische THRβ1 wurden mit 
Hochrisiko-BC-Markern wie HER2, Ki67, CD133 und N-Cadherin korreliert. Die 
Gesamtüberlebensanalyse zeigte, dass das zytoplasmatische THRβ1 mit einem günstigen Überleben 
korrelierte, wohingegen das nukleare THRβ1 eine statistisch signifikante Korrelation mit einer 
schlechten Überlebensrate aufwies. Interessanterweise erwiesen sich in unserer Kohorte, dass 
nukleäres und zytoplasmatisches THRβ1 als unabhängige Marker für schlechte bzw. gute 
Prognosen angesehen werden können. Insgesamt deuten diese Daten darauf hin, dass die 
subzelluläre Expression von THRβ1 eine wichtige Rolle bei der Onkogenese spielen könnte. 
Darüber hinaus ist die Expression von nukleärem THRβ1 ein negativer Marker, der zur 
Identifizierung von BC-Untergruppen mit hohem Risiko beitragen kann. 
 Zusammenfassend werden sowohl zytoplasmatisches PPARγ; als auch nukleäres THRβ1 als 
negative Überlebensmarker angesehen, um BC-Untergruppen mit hohem Risiko zu identifizieren. 
Der Zusammenhang von genomischen und nichtgenomischen Wirkungen von NRs kann bei der 
BC-Entwicklung eine wesentliche Rolle spielen. Daher könnte die weitere Untersuchung der 
intrazellulären Verteilung von NRs neue Erkenntnisse liefern, um eine neuartige Therapien für BC 
zu identifizieren. 
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